Keywords: Cost-effectiveness; cost-effectiveness threshold; efficiency; fairness; health technology assessment (HTA); NICE; opportunity cost; quality-adjusted life-year (QALY);
مقالات ISI (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: drug policy; reimbursement prices; health technology assessment (HTA); pricing; Romania;
Keywords: Health product assessment; Patient involvement; Healthcare democracy; Patient evidence; Health technology assessment (HTA);
Keywords: Vaccine evaluation; Vaccine policy; Core values; Health policy; Health Technology Assessment (HTA); Decision-making; MCDA; GH2035;
Keywords: medical devices; assessment; health technology assessment (HTA); ASR; improvement in actual benefit (amélioration du service rendu); AP-HP; Paris Public Hospitals (Assistance Publique-Hôpitaux de Paris); CNSA; National Solidarity Fund for Autonomy (Cais
Keywords: OR in health services; Health technology assessment (HTA); Magnetic resonance imager (MRI); Purchasing; Forecasting;
Keywords: Health economic evaluation; reimbursement; policy making; health technology assessment; pharmaceutical market; The NetherlandsGesundheits-ökonomische Evaluierung; Krankenkassenleistungen; Gesundheitspolitik; Health Technology Assessment (HTA); pharmazeuti
Building Synergy between Regulatory and HTA Agencies beyond Processes and Procedures-Can We Effectively Align the Evidentiary Requirements? A Survey of Stakeholder Perceptions
Keywords: drug development; early scientific advice; evidence generation; health technology assessment (HTA); HTA-regulatory synergy; review and reimbursement;
Comment renforcer la place des patients dans les évaluations des technologies de santé faites par les autorités de santé
Keywords: Ãvaluation des produits de santé; Implication des patients; Démocratie sanitaire; Evidence patients; Health technology assessment (HTA);
Five years of EMA-approved systemic cancer therapies for solid tumours-a comparison of two thresholds for meaningful clinical benefit
Keywords: ESMO-MCBS; Health technology assessment (HTA); Cancer drug approval; Benefit; Value;
Why do some countries approve a cancer drug and others don't?
Keywords: Health Technology Assessment (HTA); Drug reimbursement; European countries; Cancer drug-indications;
Keywords: “Dossier” automated system; health technology assessment (HTA); reimbursement lists